Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade B 23.1 2.08% 0.47
NKTR closed up 2.08 percent on Thursday, June 4, 2020, on 1.46 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical NKTR trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
Crossed Above 20 DMA Bullish 2.08%
Golden Cross Bullish 2.08%
Pocket Pivot Bullish Swing Setup 2.08%
20 DMA Resistance Bearish 5.96%
Fell Below 20 DMA Bearish 6.80%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 6.80%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Chemistry Biotechnology Biopharmaceutical Manufacturing Pharmaceutical Pain Drugs Pharmacology Ovarian Cancer Chronic Pain Morphinans Anti Infectives Metastatic Breast Cancer Pegylation Metastatic Colorectal Cancer Opioid Antagonists Diols Opioid Induced Constipation

Is NKTR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 36.85
52 Week Low 13.63
Average Volume 1,234,601
200-Day Moving Average 19.82
50-Day Moving Average 20.02
20-Day Moving Average 22.14
10-Day Moving Average 22.46
Average True Range 0.99
ADX 27.15
+DI 30.34
-DI 15.12
Chandelier Exit (Long, 3 ATRs ) 20.77
Chandelier Exit (Short, 3 ATRs ) 22.17
Upper Bollinger Band 23.76
Lower Bollinger Band 20.51
Percent B (%b) 0.8
BandWidth 14.68
MACD Line 0.69
MACD Signal Line 0.78
MACD Histogram -0.0867
Fundamentals Value
Market Cap 3.61 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -16.50
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.59
Resistance 3 (R3) 24.50 23.93 24.34
Resistance 2 (R2) 23.93 23.55 23.97 24.25
Resistance 1 (R1) 23.51 23.31 23.72 23.60 24.17
Pivot Point 22.94 22.94 23.04 22.98 22.94
Support 1 (S1) 22.52 22.56 22.73 22.61 22.03
Support 2 (S2) 21.95 22.32 21.99 21.95
Support 3 (S3) 21.53 21.95 21.86
Support 4 (S4) 21.62